Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
Related Posts
Getting EVs To Go Further Does Not Have To Be Entirely About Changing Battery Technology
As the automotive industry continues its transition to the electrical future, the importance of energy conservation is only increasing in importance. The key to global EV adoption undoubtedly lies in battery technology that must become more affordable, but automakers are also making efforts to allow electric vehicles to go further on a single charge even without changing battery technology.
2 TSX Retail Stocks To Watch- Canadian Tire (CTC) & Couche-Tard (ATD)
Canadian Tire Corporation (TSX: CTC), on Thursday, March 10, announced a C$ 3.4 billion investment plan to enhance its omnichannel capabilities and promote long-term growth. The company said this strategy aims to improve customer experiences and sales figures.
Russia Braces For Deep Recession Amid Corporate Exodus
With the Russian ruble sinking to fresh lows and global companies exiting the market, forecasts of a looming collapse of the $1.7 trillion Russian economy have grown since the Kremlin launched its military attacks on Ukraine less than two weeks